PHARMACEUTICAL PREPARATIONS
Whitehawk Therapeutics, Inc. Common Stock
WHWK
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
Open XNAS
Fundamentals
Key company ratios and reported financial statements.
Key ratios
Valuation
- Market capitalization
- $177.62M
- Price / earnings
- —
- Price / book
- 1.09×
- Price / sales
- —
- EV / sales
- —
- EV / EBITDA
- -1.21×
Profitability
- Earnings per share
- -$1.41
- Return on assets
- -48.03%
- Return on equity
- -51.13%
- Dividend yield
- 0%
Liquidity and leverage
- Debt / equity
- 0×
- Current ratio
- 16.47×
- Quick ratio
- 16.47×
- Cash ratio
- 6.61×
Cash flow
- Price / cash flow
- —
- Price / free cash flow
- —
- Free cash flow
- -$73.65M
Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.
| Line item | Q3 FY2026 Sep 30, 2026 | Q2 FY2026 Jun 30, 2026 | Q1 FY2026 Mar 31, 2026 | Q4 FY2025 Dec 31, 2025 | Q3 FY2025 Sep 30, 2025 | Q2 FY2025 Jun 30, 2025 | Q1 FY2025 Mar 31, 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $7.15M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $760K |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $6.39M |
| Selling, general and administrative | $4.81M | $5.22M | $6.29M | $5.87M | $5.2M | $5.94M | $12.82M |
| Research and development | $18.14M | $12.89M | $17.23M | $19.02M | $14.35M | $48.81M | $8.79M |
| Total operating expenses | $22.94M | $18.11M | $23.52M | $24.89M | $19.55M | $54.75M | $21.6M |
| Operating income | -$22.94M | -$18.11M | -$23.52M | -$24.89M | -$19.55M | -$54.75M | -$15.22M |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Income before taxes | -$21.21M | -$16.64M | -$22.19M | -$23.25M | -$17.75M | -$52.62M | $73.02M |
| Income taxes | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$21.21M | -$16.64M | -$22.19M | -$23.25M | -$17.75M | -$52.62M | $73.02M |
| Net income attributable to common shareholders | -$21.21M | -$16.64M | -$22.19M | -$23.37M | -$17.75M | -$52.62M | $73.02M |
| EBITDA | -$22.94M | -$18.11M | -$23.52M | -$24.89M | -$19.54M | -$54.73M | -$15.16M |
| Basic earnings per share | -$0.23 | -$0.20 | -$0.32 | -$0.34 | -$0.26 | -$0.76 | $1.84 |
| Diluted earnings per share | -$0.23 | -$0.20 | -$0.32 | -$0.34 | -$0.26 | -$0.76 | $1.83 |
Recent news
Company coverage with links to the original publishers.
No recent company news found.
Dividends
Declared distributions and recorded event dates. Forecasts are not shown.
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.
No stock split records found.